Skip to main content
Terug
CRNX logo

Crinetics Pharmaceuticals, Inc.

Datakwaliteit: 100%
Oversold
CRNX
NASDAQ Healthcare Biotechnology
€ 34,37
▼ € 0,34 (-0,98%)
Marktkapitalisatie: 3,60B
Dagbereik
€ 33,49 € 34,76
52-Weeksbereik
€ 24,10 € 57,99
Volume
1.180.232
50D / 200D Gem.
€ 45,69 / € 39,68
Vorige Slotkoers
€ 34,71

Koershistorie

Financiële Trends

Sectorvergelijking

vs Healthcare sector mediaan (627 peers)

Metriek Aandeel Sector Mediaan
P/E -7,7 0,3
P/B 3,6 2,9
ROE % -40,2 3,7
Net Margin % -6046,2 3,8
Rev Growth 5Y % 63,5 10,0
D/E 0,1 0,2

Koersdoel Analisten

Hold
€ 94,71 +175.6%
Low: € 67,00 High: € 143,00
Forward WPA
-€ 4,77
Omzet Sch.
62 M

Winstschattingen

Periode WPA Sch. Omzet Sch. Analisten
FY2030 € 4,93
€ 3,44 – € 6,33
1,6 B 1
FY2029 € 0,95
€ 0,67 – € 1,22
930 M 1
FY2028 -€ 2,47
-€ 3,72 – -€ 0,99
420 M 5

Belangrijkste Punten

Revenue grew 63,46% annually over 5 years — strong growth
Debt/Equity of 0,05 — conservative balance sheet
Negative free cash flow of -383,68M
Revenue growth is accelerating — 1Y growth exceeds 5Y average by 577,25%
Capital intensive — 74,87% of revenue goes to capex

Groei

Revenue Growth (5Y)
63,46%
Revenue (1Y)640,71%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
-40,17%
ROIC-37,24%
Net Margin-6046,22%
Op. Margin-6714,77%

Veiligheid

Debt / Equity
0,05
Current Ratio12,32
Interest Coverage0,00

Waardering

P/E Ratio
-7,73
P/B Ratio3,63
EV/EBITDAN/A
Dividend Yield0,00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 640,71% Revenue Growth (3Y) 38,48%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) 63,46% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 7,70M Net Income (TTM) -465,32M
ROE -40,17% ROA -40,98%
Gross Margin 35,47% Operating Margin -6714,77%
Net Margin -6046,22% Free Cash Flow (TTM) -383,68M
ROIC -37,24% FCF Growth (3Y) N/A
Safety
Debt / Equity 0,05 Current Ratio 12,32
Interest Coverage 0,00 Dividend Yield 0,00%
Valuation
P/E Ratio -7,73 P/B Ratio 3,63
P/S Ratio 467,61 PEG Ratio -0,28
EV/EBITDA N/A Dividend Yield 0,00%
Market Cap 3,60B Enterprise Value 3,55B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 7,70M 1,04M 4,01M 4,74M 1,08M
Net Income -465,32M -298,41M -214,53M -163,92M -107,64M
EPS (Diluted) -4,95 -3,69 -3,69 -3,15 -2,80
Gross Profit 2,73M 1,04M 4,01M 4,74M 1,08M
Operating Income -516,77M -338,85M -222,61M -167,88M -107,70M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 1,14B 1,43B 635,35M 352,18M 351,02M
Total Liabilities 143,41M 109,79M 96,25M 35,85M 19,07M
Shareholders' Equity 992,08M 1,32B 539,11M 316,33M 331,94M
Total Debt 48,54M 51,72M 51,73M 3,08M 3,07M
Cash & Equivalents 101,54M 264,55M 54,90M 32,67M 200,70M
Current Assets 1,05B 1,38B 574,15M 345,18M 344,72M
Current Liabilities 85,07M 59,68M 43,94M 27,72M 16,00M

Strategiescores

This stock passed the criteria for 1 strategy

Score = fit strength (0–100)
Rank = position among all matches
#14 of 76
76

Recente Activiteit

Ingestapt Capital Heavy Grower
Mar 24, 2026